

SHARON  
REGIONAL  
HEALTH  
SYSTEM



*Advanced Care  
Close to Home*

Advanced Wound Recovery Center  
Behavioral Health Services  
Brain Attack/Stroke Center  
Breast Care Center  
Cancer Care Center  
Chest Pain Emergency Center  
Comprehensive Pain Management Center  
Corporate Health Services  
Diabetes Center  
Ear, Nose, Throat & Hearing Center  
Emergency Care Center  
Express Care  
Family Medicine Centers  
HealthPLACE  
Heart Institute  
Home Health Agency  
Hospice/Palliative Care Hospital  
Rehabilitation Services  
School of Nursing  
School of Radiography  
Sports Medicine Services  
Surgical Services  
Transitional Care Unit  
Women's Center

Facility Locations  
Sharon  
Hermitage  
Mercer  
Greenville  
Brookfield, OH

Main Campus  
740 East State Street  
Sharon, PA 16146-3395  
724-983-3911  
www.sharonregional.com

John A. Zidasek  
President & CEO

May 2, 2007

NMS 81

U.S. Nuclear Regulatory Commission  
Materials Licensing Branch  
Region 1  
475 Allendale Road  
King of Prussia, Pennsylvania 19406

03013670

RE: Materials License #37-01626-04

Dear Sir or Madam,

We wish to add Surendra Pawar, M.D. as an authorized user for privileges under 10 CFR 35 parts 100, 200 and 300. Please refer to the Radioactive Materials License for Alle-Kiski Medical Center, Natrona Heights, Pa. # 37-02584-01.

If you have any questions or require additional information, please do not hesitate to contact the undersigned.

Sincerely,

John R. Janoso, Jr.  
Vice President/Chief Information Officer

JoAnne Esposito, B.A., R.T.R.  
Director of Medical Imaging

2007 MAY -9 PM 12: 29

RECEIVED  
REGION 1

140500  
NMSS/RGN1 MATERIALS-002

**AUTHORIZED USER TRAINING AND EXPERIENCE  
AND PRECEPTOR ATTESTATION**  
(for uses defined under 35.100, 35.200, and 35.500)  
[10 CFR 35.190, 35.290, and 35.590]

APPROVED BY OMB: NO. 3150-0120  
EXPIRES: 10/31/2008

Name of Proposed Authorized User

*Surendra V. Pawar*

State or Territory Where Licensed

*PA*

Requested Authorization(s) (check all that apply)

35.100 Uptake, dilution, and excretion studies

35.200 Imaging and localization studies

35.500 Sealed sources for diagnosis (specify device \_\_\_\_\_)

**PART I -- TRAINING AND EXPERIENCE**  
(Select one of the three methods below)

\* Training and Experience, including board certification, must have been obtained within the 7 years preceding the date of application or the individual must have obtained related continuing education and experience since the required training and experience was completed. Provide dates, duration, and description of continuing education and experience related to the uses checked above.

**1. Board Certification**

a. Provide a copy of the board certification.

b. If using only 35.500 materials, stop here. If using 35.100 and 35.200 materials, skip to and complete Part II Preceptor Attestation.

**2. Current 35.390 Authorized User Seeking Additional 35.290 Authorization**

a. Authorized user on Materials License \_\_\_\_\_ meeting 10 CFR 35.390 or equivalent Agreement State requirements seeking authorization for 35.290.

b. Supervised Work Experience.  
(If more than one supervising individual is necessary to document supervised work experience, provide multiple copies of this section.)

Description of Experience	Location of Experience/License or Permit Number of Facility	Clock Hours	Dates of Experience*
Eluting generator systems appropriate for the preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs			

**Total Hours of Experience:**

Supervising Individual

License/Permit Number listing supervising individual as an authorized user

Supervisor meets the requirements below, or equivalent Agreement State requirements (check all that apply).

35.290

35.390 + generator experience in 32.290(c)(1)(ii)(G)

**AUTHORIZED USER TRAINING AND EXPERIENCE  
AND PRECEPTOR ATTESTATION**  
(for uses defined under 35.300)  
[10 CFR 35.390, 35.392, 35.394, and 35.396]

APPROVED BY OMB: NO. 3150-0120  
EXPIRES: 10/31/2008

Name of Proposed Authorized User

*Surendra V. Pawar*

State or Territory Where Licensed

*PA*

Requested Authorization(s) (check all that apply):

35.300 Use of unsealed byproduct material for which a written directive is required

OR

35.300 Oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)

35.300 Oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)

35.300 Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

35.300 Parenteral administration of any other radionuclide for which a written directive is required

**PART I -- TRAINING AND EXPERIENCE**  
(Select one of the three methods below)

Training and Experience, including board certification, must have been obtained within the 7 years preceding the date of application or the individual must have related continuing education and experience since the required training and experience was completed. Provide dates, duration, and description of continuing education and experience related to the uses checked above.

**1. Board Certification**

- a. Provide a copy of the board certification.
- b. For 35.390, provide documentation on supervised clinical case experience. The table in section 3.c. may be used to document this experience.
- c. For 35.396, provide documentation on classroom and laboratory training, supervised work experience, and supervised clinical case experience. The tables in sections 3.a., 3.b., and 3.c. may be used to document this experience.
- d. Skip to and complete Part II Preceptor Attestation.

**2. Current 35.300, 35.400, or 35.600 Authorized User Seeking Additional Authorization**

a. Authorized User on Materials License 37-02584-01 under the requirements below or equivalent Agreement State requirements (check all that apply):

35.390     35.392     35.394     35.490     35.690

b. If currently authorized for a subset of clinical uses under 35.300, provide documentation on additional required supervised case experience. The table in section 3.c. may be used to document this experience. Also provide completed Part II Preceptor Attestation.

c. If currently authorized under 35.490 or 35.690 and requesting authorization for 35.396, provide documentation on classroom and laboratory training, supervised work experience, and supervised clinical case experience. The tables in sections 3.a., 3.b., and 3.c. may be used to document this experience. Also provide completed Part II Preceptor Attestation.

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES  
Amendment No. 46

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

- 1. Alle-Kiski Medical Center  
Allegheny Valley Hospital
- 2. 1301 Carlisle Street  
Natrona Heights, Pennsylvania 15065

In accordance with the letter dated July 26, 2006

3. License number 37-02584-01 is amended in its entirety to read as follows:

4. Expiration date November 30, 2015

5. Docket No. 030-03024  
Reference No.

6. Byproduct, source, and/or special nuclear material

- A. Any byproduct material permitted by 10 CFR 35.100
- B. Any byproduct material permitted by 10 CFR 35.200
- C. Any byproduct material permitted by 10 CFR 35.300
- D. Any byproduct material permitted by 10 CFR 35.400

7. Chemical and/or physical form


- A. Any
- B. Any
- C. Any
- D. Sealed Sources (Amersham Health Model 6701 OncoSeed and Bard Brachytherapy, Inc. Model STM 1251)
- E. Sealed Source (North American Scientific Model MED 3601)

8. Maximum amount that licensee may possess at any one time under this license

- A. As needed
- B. As needed
- C. 200 millicuries
- D. 1 curie
- E. 2 millicuries

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- E. Possession and storage only incident to disposal.



NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 4 PAGES

MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number  
37-02584-01

Docket or Reference Number  
030-03024

Amendment No. 46

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 1301 Carlisle Street, Natrona Heights, Pennsylvania.
- 11. The Radiation Safety Officer for this license is Mark S. Colella, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Mark S. Colella, M.D.	35.100; 35.200; 35.300
Bart J. Friedman, M.D.	35.100; 35.200
Gregory C. Mleckowski, M.D.	35.100; 35.200; 35.300
Warren Ostlund, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction
Edward R. Scheid, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
David P. Weinstein, M.D.	35.100; 35.200; 35.300
Janel Tabas, M.D.	35.100; 35.200; 35.300
Surendra V. Pawar, M.D.	35.100; 35.200; 35.300
Youssef Michel Arshoun, M.D.	35.400
Athanasio Colonias, M.D.	35.400
Russell Fuhrer, M.D.	35.400
Stephen M. Katlovits, M.D.	35.400
Vinod Shah, M.D.	35.400

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number:  
37-02584-01

Docket or Reference Number:  
030-03024

Amendment No. 46

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."



NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
37-02584-01

Docket or Reference Number  
030-03024

Amendment No. 46

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated May 27, 2005 (ML051600402)

B. Letter dated July 26, 2006 (ML062220114)



For the U.S. Nuclear Regulatory Commission

Date August 25, 2006

By Original signed by Richard McKinley

Richard McKinley  
Medical Branch  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406

Friday, August 25, 2006 3:28:37 PM

This is to acknowledge the receipt of your letter/application dated

5/2/2007, and to inform you that the initial processing which includes an administrative review has been performed.

*Attched. 37-01626-04* There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 140500.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.